- Trivehexin radiopharmaceuticals being developed for imaging and treatment of cancers expressing αvβ6-integrin
- Pancreatic ductal adenocarcinoma is primary indication due to high unmet need
- Potential follow-on indications include non-small cell lung cancer, head and neck, and colorectal cancer
Radiopharm is developing Trivehexin as a novel radiopharmaceutical for imaging and treatment of pancreatic cancer. Trivehexin is a proprietary peptide-based molecule that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancreatic carcinoma cells, making it an attractive diagnostic and therapeutic target.
“Orphan Drug Designation for RAD 301 comes on top of FDA IND approval for a Phase I clinical trial in pancreatic cancer, which is planned to start in the next few weeks in the United States,” said
The Company now holds two FDA Orphan Drug Designations, along with the LRRC15 antibody DUNP19 for the treatment of patients with osteosarcoma. Designation is granted for a drug or biologic product with the potential to diagnose, prevent or treat rare diseases and conditions. Recipients of the designation receive benefits and incentives including tax credits for qualified clinical trials, exemption from user fees and a potential seven years of market exclusivity if the drug is approved.
Radiopharm signed an exclusive licensing agreement with
About
Authorised on behalf of the
For more information:
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Investor Relations
P: +1 917 679 9282
E: tim@lifesciadvisors.com
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
Source:
2023 GlobeNewswire, Inc., source